Skip to main content
BOTANIX PHARMACEUTICALS LTD logo

BOTANIX PHARMACEUTICALS LTD — Investor Relations & Filings

Ticker · BOT ISIN · AU000000BOT2 ASX Manufacturing
Open in API
Filings indexed 1,209 across all filing types
Latest filing 2019-09-05 Regulatory Filings
Country AU Australia
Listing ASX BOT

About BOTANIX PHARMACEUTICALS LTD

https://botanixpharma.com/

Botanix Pharmaceuticals Ltd is a clinical-stage pharmaceutical company focused on the development and commercialization of novel topical treatments for serious skin conditions. The company utilizes its proprietary Permetrex™ skin delivery technology, which is designed to improve the delivery of active ingredients through the skin. Its primary product, Sofdra™ (sofpironium bromide), is an FDA-approved prescription topical gel for the treatment of primary axillary hyperhidrosis. The company's research and development pipeline also includes clinical-stage candidates for the treatment of acne, rosacea, and atopic dermatitis. Botanix aims to address significant unmet medical needs in dermatology by providing innovative therapeutic solutions with enhanced safety and efficacy profiles.

Recent filings

Filing Released Lang Actions
BOT antimicrobial data presented at ASM-ESCMID Conference 3 pages 237.4KB
Regulatory Filings Classification · 95% confidence The document is an ASX/Media Release dated 6 September 2019 from Botanix Pharmaceuticals. It discusses the presentation of antimicrobial data at a scientific conference, highlighting research findings and future development plans. The content is a news announcement about scientific progress and company updates rather than a financial report, regulatory filing, or management discussion. There are no financial statements, regulatory certifications, or voting results. The document is a press release providing information to investors and the public about recent scientific presentations and company activities. Therefore, it fits best under the category of Regulatory Filings (RNS) as a general regulatory announcement and company update that does not fit other specific categories.
2019-09-05 English
Appendix 3B 12 pages 295.7KB
Capital/Financing Update Classification · 95% confidence The document is titled 'Appendix 3B New issue announcement' and contains detailed information about the issuance of new securities, including unlisted options, their terms, issue price, purpose, and compliance with ASX rules. It includes sections on the number and class of securities issued, shareholder approvals, quotation requests, and calculation of placement capacity under ASX rules. Appendix 3B is a standard form used in Australian securities markets to announce new issues of securities and apply for their quotation on the ASX. The content is regulatory in nature, focused on the announcement of a new share issue and related securities, not a financial report or earnings release. It is not a full financial report, management discussion, or earnings call transcript. It is also not a proxy statement, dividend notice, or legal proceeding report. Given the detailed nature and regulatory compliance focus, this document fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes.
2019-09-03 English
Final Director's Interest Notice MC 2 pages 204.5KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Z Final Director’s Interest Notice' and references ASX listing rule 3.19A.3 and section 205G of the Corporations Act. It details the director's relevant interests in securities, including shares held directly and indirectly, and notes the date the director ceased to be a director. This is a report of personal share transactions or holdings by a company director, which aligns with the definition of Director's Dealing filings. The document length is short and focused solely on director share interests, with no financial statements or other report content. Therefore, the appropriate classification is Director's Dealing (DIRS).
2019-08-25 English
Director Temporary Leave of Absence 3 pages 204.7KB
Board/Management Information Classification · 95% confidence The document is an ASX/Media Release dated 23 August 2019 announcing that Executive Director Matthew Callahan is taking a temporary leave of absence from the Botanix Board. It discusses management changes and company operational updates but does not contain financial statements or detailed financial data. The document is a corporate announcement about board/management changes rather than a full report or financial disclosure. Therefore, it fits the category of Board/Management Information (MANG). The document length is 6386 characters, which is sufficient for a detailed announcement but does not include financial results or report data. Hence, the classification is MANG with high confidence.
2019-08-22 English
Appendix 4E and Annual Report 79 pages 1.1MB
Annual Report Classification · 100% confidence The document is titled 'Appendix 4E Final report' and includes detailed financial information for the year ended 30 June 2019, including profit and loss, net tangible assets, dividends, and a comprehensive Directors' Report. It also contains an Auditor's Independence Declaration, consolidated financial statements, notes, Directors' declarations, and an Independent Auditor's Report. The document references compliance with accounting standards and includes detailed corporate governance and director information. The length is substantial (15,000 characters), and the content is consistent with a full annual report rather than a brief announcement or summary. The presence of full financial statements and detailed management discussion confirms this is the official yearly report covering company activity and full financial performance. Therefore, the document should be classified as an Annual Report (10-K).
2019-08-19 English
Appendix 4G 11 pages 188.2KB
Governance Information Classification · 95% confidence The document is titled 'Appendix 4G' and references ASX Listing Rules 4.7.3 and 4.10.3, which relate to corporate governance disclosures that must accompany the annual report. It includes a detailed key to disclosures against the ASX Corporate Governance Council Principles and Recommendations for the financial year ended 30 June 2019. The document is a corporate governance statement that is part of or accompanies the annual report, providing detailed governance practices and compliance with recommendations. It is not the full annual report itself but a governance disclosure document required to be lodged with the ASX alongside the annual report. Given the content and regulatory references, this document fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices. The document length (15,000 characters) and detailed governance content support this classification rather than a brief announcement or a full annual report.
2019-08-19 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.